Thus, the administration of GLP-1RAs may be the most promising method of treating patients at risk of stroke or immediately after a stroke, although further studies are undoubtedly needed to confirm the effect of GLP-1RAs on stroke risk in patients with T2DM
The FDA has approved various formulations for different indications based on clinical trial evidence
The dose dependent relationship of SGLT2i and incidence of DKA remains unclear and further investigation is warranted
Comfort, convenience, and consistency should guide injection site selection, provided injections are performed correctly and sites are rotated
The best fiber supplement for GLP-1 guide compares your options
Low adherence may also relate to lower public and clinician awareness of the need for long-term use after a weight goal, health goal, or plateau is reached